跳到正文
原文
Medical Xpress·· 9 天前精选AI 评分70

停用Ozempic可能对健康有害

Stopping Ozempic may be bad for your health

AI 导读

一项研究发现,在2型糖尿病患者中停用GLP-1药物与继续治疗相比,心血管事件和死亡风险翻倍。但研究无法确定停药是否直接导致风险增加,或患者本身健康状况较差。

推荐理由

研究发现停用GLP-1药物可能增加心血管风险,但具体机制尚需进一步研究。

正文
Stopping Ozempic may be bad for your health
Credit: Haberdoedas on Unsplash

In people with type 2 diabetes (T2D) and no established cardiovascular disease (CVD), starting glucagon-like peptide-1 receptor agonist (GLP-1) treatment and then stopping is associated with twice the combined risk of heart attack, stroke or death compared with staying on treatment, according to a study published in The Lancet Regional Health—Europe.

However, as the study was observational, it cannot determine whether discontinuing GLP-1s directly causes the increased risk or whether people who stop were already in poorer health. The researchers did not know why people stopped, which could include side effects, cost or illness such as frailty or cancer.

GLP-1s reduce cardiovascular events, such as heart attacks and strokes, and death in people with T2D and in some people with obesity, but up to 50% of people stop treatment within the first year. While stopping GLP-1s is linked to weight gain and worsening of several cardiometabolic risk factors, such as blood sugar levels and blood pressure, it remains unclear if stopping treatment increases the risk of cardiovascular events and death compared with continued treatment.

Researchers analyzed electronic medical records from more than 300 diabetes clinics in the Italian Association of Clinical Diabetologists (AMD) database, collected between 2004 and 2024, identifying over 80,000 people with T2D and no established CVD who had started a GLP-1. People who continued treatment took a GLP-1 for nearly three years on average, compared with just over one year for those who stopped.

The combined risk of nonfatal heart attack, nonfatal stroke or death from any cause was about twice as high in people who stopped GLP-1 treatment as in those who continued. This equates to roughly four events per 100 people per year among those who stopped, compared with two per 100 among those who continued. Deaths from any cause were also higher (about 2.2 versus 0.5 per 100 people per year), but the authors say stopping alone is unlikely to explain a gap this large. Among those who stopped, both risks were higher in people with obesity (body mass index [BMI] of 30 or over) than in those without (BMI under 30).

After people stopped GLP-1 treatment, their weight, blood sugar and blood pressure changed only modestly, and by similar amounts whether or not they went on to have a heart attack or stroke or die. This suggests that worsening weight, blood sugar and blood pressure may not fully explain why those who stopped had a higher risk.

The authors say this study suggests that, in people with T2D and no established CVD, long-term GLP-1 use may be important for maintaining their overall health benefits, but more research is needed to determine if stopping GLP-1s directly contributes to increased cardiovascular risk or instead acts as a marker for patients with worsening health and/or underlying cardiovascular risk.

More information

The Lancet Regional Health—Europe (2026). DOI: 10.1016/j.lanepe.2026.20101881

Who's behind this story?

Lisa Lock

Lisa Lock

BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: Stopping Ozempic may be bad for your health (2026, November 10) retrieved 10 November 2026 from https://medicalxpress.com/news/2026-11-ozempic-bad-health.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com